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Background: Engraftment of primary pancreas ductal adenocarcinomas (PDAC) in mice to generate patient-derived
xenograft (PDX) models is a promising platform for biological and therapeutic studies in this disease. However,
these models are still incompletely characterized. Here, we measured the impact of the murine tumor environment
on the gene expression of the engrafted human tumoral cells.
Methods: We have analyzed gene expression profiles from 35 new PDX models and compared them with
previously published microarray data of 18 PDX models, 53 primary tumors and 41 cell lines from PDAC. The results
obtained in the PDAC system were further compared with public available microarray data from 42 PDX models,
108 primary tumors and 32 cell lines from hepatocellular carcinoma (HCC). We developed a robust analysis protocol
to explore the gene expression space. In addition, we completed the analysis with a functional characterization of
PDX models, including if changes were caused by murine environment or by serial passing.
Results: Our results showed that PDX models derived from PDAC, or HCC, were clearly different to the cell lines
derived from the same cancer tissues. Indeed, PDAC- and HCC-derived cell lines are indistinguishable from each
other based on their gene expression profiles. In contrast, the transcriptomes of PDAC and HCC PDX models can be
separated into two different groups that share some partial similarity with their corresponding original primary
tumors. Our results point to the lack of human stromal involvement in PDXs as a major factor contributing to their
differences from the original primary tumors. The main functional differences between pancreatic PDX models and
human PDAC are the lower expression of genes involved in pathways related to extracellular matrix and hemostasis
and the up- regulation of cell cycle genes. Importantly, most of these differences are detected in the first passages
after the tumor engraftment.
Conclusions: Our results suggest that PDX models of PDAC and HCC retain, to some extent, a gene expression
memory of the original primary tumors, while this pattern is not detected in conventional cancer cell lines.
Expression changes in PDXs are mainly related to pathways reflecting the lack of human infiltrating cells and the
adaptation to a new environment. We also provide evidence of the stability of gene expression patterns over
subsequent passages, indicating early phases of the adaptation process.Background
Patient-derived xenograft (PDX) models are becoming a
common platform for research and clinical purposes [1].
The establishment of PDX models to study cancer biology
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article, unless otherwise stated.successfully applied to many cancer types [2-5]. Xeno-
grafting of human primary carcinomas is in fact the only
method currently available that permits the propagation
of a significant proportion of carcinomas [6-8] and has
many advantages over tumor-derived cell lines maintained
in vitro [9-11]. Both cell lines and PDX models permit the
removal of contaminating non-neoplastic human cells
from the human tumors. However, the tissue architecture
is only partially maintained in PDXs [2,11,12] with mouse
stromal cells substituting for human stromal cells [13]. In
general, the results obtained using PDX models in miceCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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those from cell lines [11,14].
Pancreas ductal adenocarcinoma (PDAC) is usually
diagnosed in advanced stages after it has metastasized
to regional lymph nodes, liver or lung [15] and the me-
dian survival after diagnosis is approximately 8 months
[16]. PDAC is notorious for how difficult it is to obtain
biological material to study the disease. In addition,
standard treatments have a very low percentage of suc-
cess and the short survival time of the patients makes it
challenging to search for alternative therapies [17]. For
these reasons, PDX models are particularly attractive
for studying PDAC.
Despite their advantages over cell lines, fresh tumors
xenografted in mice show differences from the original pri-
mary tumors [11]. For example, the proportion of murine
stromal cells in PDAC PDXs is lower than the proportion
of human stromal cells in the original primary tumors (our
experimental observations). Thus, caution should be taken
when interpreting the results obtained using these models.
A study by Gadaleta et al. [18] analyzed the so-called 'pan-
creas expression space' by combining publicly available
gene expression array datasets studied with the Affymetrix
Human Genome U133 Plus 2.0 Array platform. This pan-
creas expression space included healthy pancreatic tissue,
human primary pancreas cancer, non-tumoral tissue adja-
cent to tumor, tumor-derived cell lines and PDX models.
These authors applied a statistical method (principal com-
ponent analysis) to explore how the different samples clus-
tered in the two first principal components [18]. Their
main findings were that (1) non-tumoral tissue adjacent
to tumor was different to healthy pancreatic tissue, (2)
primary tumors and tumor adjacent samples clustered
together, and (3) PDXs and cell lines clustered in two
other groups. One of their main conclusions was 'that
ectopic subcutaneous xenografts and cell line models
do not effectively represent changes occurring in pan-
creatic cancer'. This work highlighted the importance
of understanding better the extent to which the mouse
environment is altering the gene expression of the im-
planted human tumoral cells.
Our central goal was to understand how the ectopic
xenograft mouse environment affects the expression
phenotype of PDAC cells. We developed a robust ana-
lysis protocol to explore the PDAC expression space, in-
cluding human primary tumors, tumor-derived cell lines
and PDX models. We used expression data from primary
tumors, PDX models and cell lines derived from PDACs.
In addition, we used hepatocellular carcinoma (HCC) to
study if PDXs and cell lines share any characteristics
with the original primary tumors. The study shows
that the gene expression profiles of PDAC and HCC
PDX models conserved substantial similarity with their
original primary tissues, while all cell lines clusteredtogether, independently of their tissues of origin. How-
ever, we also identified several biological pathways that
showed differential expression between PDX models and
tumors, such as extracellular matrix organization, likely
due to replacement of the human stroma by murine ele-
ments, and up-regulation of cell cycle and DNA replica-
tion that are indicative of higher proliferation. We also
show that these changes happened at initial stages after
engrafting and were stable over different passages.
Materials and methods
Generation of PDX models and sample processing
We performed gene expression profiling for 35 new PDX
models of PDACs xenografted in nude mice and 2 human
primary tumor samples. PDX models were established fol-
lowing an already described protocol [1]. Mice used in this
research have been treated humanely according to the reg-
ulations laid down by the CNIO Bioethics Committee and
the relevant EC guidelines (directive 86/609/EEC), with
due consideration to the alleviation of distress and dis-
comfort. RNA was extracted using Qiagen RNeasy Mini
kits (QIAGEN Inc., Valencia, CA, USA) and was hybrid-
ized in GeneChip® Human Genome U133 Plus 2.0 Array,
Affymetrix (Santa Clara, CA, USA). The data generated in
this publication have been deposited in NCBI’s Gene Ex-
pression Omnibus (GEO) and are accessible through GEO
Series accession number GSE51798.
Public datasets
In addition to the new gene expression profiles specific-
ally obtained for this study, we retrieved data from GEO
series [19,20] that were hybridized in the same platform
as our models (Human Genome U133 Plus 2.0 Array).
We also added the data from a dataset with 18 expres-
sion profiles from PDX models (GSE9599) previously
described [21]. We downloaded expression data for 51
original tumor samples available from Badea et al. [22]
and Pei et al. [23] published in datasets GSE15471 and
GSE16515. We also used gene expression profiles of 22
cell lines from Maupin et al. [24] and 19 from Collisson
et al. [25]. These two datasets have data from 11 cell
lines in common. All samples corresponded or were de-
rived from adenocarcinomas.
In addition, we compiled an HCC dataset with 182
expression profiles, including data from 42 HCC PDX
models [26], 32 cell lines [26,27] (these two datasets have
data from 5 cell lines in common) and 108 primary HCC
[26,28-31] samples. All samples corresponded to carcin-
omas, except two cell lines (HuH-6 and NCI-H684) that
were derived from hepatoblastomas. All datasets used to
create gene expression spaces are summarized in Table 1.
We also downloaded two datasets of expression profiles
of pancreatic primary tumors and metastases, GSE42952
[32] and GSE34153 [33]. GSE42952 was normalized and
Table 1 Microarray datasets used in this study
Pancreas Liver
Samples GEO accession Samples GEO accession
PDX models 53 GSE9599 [21], GSE51798 42 GSE6465 [26]
Cell lines 41 (11 repeated) GSE17891 [25], GSE21654 [24] 32 (5 repeated) GSE6465 [26], GSE36133 [27]
Primary Tumors 53 GSE15471 [22], GSE16515 [23], GSE51798 108 GSE6465 [26], GSE6222 [28], GSE9843 [29-31]
Number of samples and GEO accession for all datasets used in the study to create gene expression spaces. The new dataset that was generated in this study is
indicated in bold.
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samples in the HGU133 Plus 2.0 Array platform. The
GSE34153 dataset corresponds to the Agilent 4x44 K
whole human genome array platform and we used the
normalized data available in GEO series.
Analysis protocol
We used the frozen robust multiarray analysis (fRMA)
method for preprocessing and normalization of microar-
rays. fRMA pre-processes arrays individually and allows
addition of new samples to a previously normalized
dataset [34], a feature that is very convenient when new
samples are included in a pre-existing dataset. We then
utilized the Gene Expression Barcode method included
in the fRMA R package that converts normalized expres-
sion intensities into expression binary calls (silenced or
expressed). The main benefit of this approach is that it
minimizes batch effects and reduces noise [35]. As we
were not using expression intensities but yes/no expres-
sion calls, we used the multiple correspondence analysis
(MCA) method [36] to explore the pancreas expression
space. MCA is equivalent to principal component ana-
lysis (PCA) when working with qualitative data instead
of continuous variables. In this work we have adapted a
methodological protocol, previously applied to multiple
sequence alignments, for the automatic extraction of
relevant signatures from MCA results [37]. In brief, our
protocol performs a MCA on a vectorial representation
of multiple 'barcoded' microarray data in a high dimen-
sional space. MCA produces a new multidimensional
space so that the accumulated variance of the coordi-
nates of every probe in a subset of dimensions is opti-
mal. The MCA space is reduced to a low dimensional
one preserving most of the original information but
filtering the main sources of noise. Our protocol estab-
lishes a low dimensional space composed of those
dimensions that incorporate results in a statistically
significant increment of the information. The number of
informative dimensions (those that explain most of the
total variance) is selected according to the P-value of a
Wilcoxon test between contiguous axes. Additional axes
are included in the expression space if the P-value is
lower than 0.01. Robust unsupervised k-means clustering
is performed iteratively on this reduced space (definedby the informative dimensions) for a range of pre-specified
numbers of groups (from 2 to 50). Finally, optimal
clustering solutions are detected as those maximizing
the Calinsky’s and Harabsz’s (CH) index [37].
Estimation of non-tumoral component and correction for
its effect
We measured the proportion of stromal and infiltrating
immune cells using ESTIMATE [38], a gene expression
signature-based method that estimates tumor purity
from gene expression data. ESTIMATE scores were cal-
culated using the original R code from the authors using
the default parameters for the Affymetrix arrays. To
remove the contribution of human non-tumoral infiltrat-
ing (hNTI) cells to the PDX primary tumor expression
space, we first generated an expression space without
the signature genes used by ESTIMATE. Then, we re-
moved the gene expression signal directly relating to the
effect of hNTI cells from remaining genes using simple
linear regression models. We fitted two linear models,
one for the first component and the other for the second
component, using in both cases the ESTIMATE score as
the explanatory variable (R2 = 0.04, P-value = 0.002 and
R2 = 0.83, P-value <2.2 × 10−16, respectively; Additional
file 1). Next, we removed the non-tumoral trend of each
component using the corresponding linear regression
models. The regression residuals of each model were
used to generate a new gene expression space corrected
for the contribution of non-tumoral infiltrating cells.
Pathway enrichment analyses
To study differences between original patients’ tumors
and PDX models we calculated the number of times that
each gene was called as 'expressed' in each group, or its
'expression frequency'. Here we considered that a gene
was expressed if any of the probes detecting that gene in
the microarray was called as 'expressed' according to
the Barcode method. The difference in expression fre-
quency for each gene between each group was obtained
by subtracting the gene expression frequency in PDX
from the gene expression frequency in primary tumors.
We ranked the values of differences in expression
frequency and performed gene set enrichment analyses
(GSEAs) with the GseaPreranked tool of the GSEA
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in Reactome [40]. A total of 621 pathways were testable
after the default filtering step (at least 15 genes and no
more than 500 genes in each gene set). We grouped to-
gether similar significant pathways (false discovery rate
(FDR) <0.05) as ‘functional groups’, guided by the Reac-
tome hierarchy. For comparisons of primary tumors
and metastases [32,33], we used the normalized expres-
sion matrices as input for GSEA to test if functional
groups were differentially expressed between metasta-
ses and primary tumors. We used t-test as the metric
for ranking genes.
Differential expression between different passages
We used the Limma package [41] to test differential
gene expression between four patients’ tumors and
PDX models developed from them at different passages
[42]. We created a linear model with information about
number of passages: primary original tumor (F0), 5th
passage (F5) and 10th passage (F0), using each patient
as blocking information. Then we contrasted F0 versus
F5, F5 versus F10 and F0 versus F10. After each
contrast analysis, we ranked genes according to their
t-statistic and used the GseaPreranked tool (see above)
to analyze if the expression levels of the genes changed
throughout passages.
Results and discussion
Pancreas and liver cancer gene expression spaces
We compiled a PDAC gene expression dataset compris-
ing a total of 147 PDAC and PDAC-derived profiles,
including 53 PDX models, 53 whole-tissue primary
PDACs and 41 cell lines (Table 1), in part collected from
databases and in part derived for this study. We proc-
essed all data using the same analysis protocol, trans-
forming the expression intensities into expression calls
[34,35]. Then, we used our MCA implementation to
explore quantitatively the transcriptional space of bio-
logical samples based on their gene expression binary
profiles (expressed or not expressed; see Materials and
methods for details). Figure 1A shows the first two
dimensions of the PDAC expression space explaining
64% of the variance (49% by the first axis and 15% by
the second). The distribution of the samples in the first
and second axes is significantly different (P-value =
1.7 × 10−4, Wilcoxon test), while adding a third dimen-
sion to the expression space does not result in a signifi-
cant gain of information (P-value = 0.08; significance
threshold = 0.01).
The MCA results clearly show that the human tumor
samples, PDX models and cell lines were three distinct
groups (Figure 1A) based on the transcriptional profile
of the complete genome as represented in the arrays.
In fact, k-means clustering of the space created bythe MCA found an optimal solution that corresponds
to three clusters (k-means = 3, CH index = 199.541): (1)
primary original tumors, (2) PDXs and (3) cell lines. Simi-
lar results were obtained when analyzing the normalized
intensities with PCA or by hierarchical clustering of the
expression calls (Figures S1A and S2A in Additional file 1).
Therefore, based on expression profiles, PDX models and
cell lines, considered globally, are as different from the
original tumors as they are from each other.
To compare our results for PDAC with other cancer
types, we used publicly available HCC microarray data,
for which we could gather a sufficiently large collection
of human primary tumors, PDX models and cell lines.
We were able to compile a dataset with a total of 182
expression profiles from HCC, including 42 HCC PDX
models, 32 cell lines and 108 primary HCCs. We applied
the same analysis protocol used for the PDAC data.
Figure 1B shows the HCC transcriptional space gener-
ated by the first two dimensions of the MCA (Wilcoxon
test P-value = 1.6 × 10−7), which explain 57% of the vari-
ance (41% by the first axis and 16% by the second). HCC
PDX models and cell lines were also located in different
areas of the HCC expression space (Figure 1B). Indeed,
the k-means clustering of the space also had an optimal
solution corresponding to three clusters (k-means = 3,
CH index = 236.304): (1) human primary tumors, (2)
PDX models and (3) cell lines. Similar clustering of the
samples was obtained using alternative methods (PCA of
expression intensities and hierarchical clustering of ex-
pression calls; Figures S1B and S2B in Additional file 1).
The results obtained with the HCC samples were in
agreement with the previously shown PDAC clusters,
where the global expression of primary tumors, PDX
models and cell lines produced three distinct groups.
Our results in PDAC and HCC confirmed previous
observations made in PDAC [18] about the differences
between primary tumors, cell lines and PDX models in
terms of their expression profiles. This scenario high-
lights the influence of the cellular environment in the
global expression of human primary tissue samples, cell
lines and PDX models. We reasoned that the PDX-
associated milieu may affect similarly to different types
of human tumors, so we next investigated to what
extent the gene expression of the human tumoral cells
changes when engrafted in PDX models focusing on
PDAC and HCC.
Conservation of primary tumor gene expression signals in
PDXs but not in cell lines
It is reasonable to think that xenografted cells may keep
a gene expression signature specific to their tumor of
origin. However, if the mouse microenvironment induces
similar changes in any cell type implanted into mice,
then the gene expression of any cell type could acquire
Figure 1 MCA gene expression spaces from PDAC and HCC. (A) PDAC gene expression space. (B) HCC gene expression space. The
percentage of variance explained by each axis is indicated between parentheses. Each point represents the expression pattern from a sample.
Grey lines represent the resulting clusters from k-means clustering for k = 3 (selected as the optimal clustering result; see Materials and methods).
Each line joins a sample with the centroid of its cluster. (A) In pancreas, all PDX models and cell lines were derived from adenocarcinomas. (B) In
liver, all samples came from carcinomas, except two cell lines that were derived from hepatoblastomas. See text for details. See Figures S1 and S2
in Additional file 1 for additional results using PCA and hierarchical clustering.
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ginal expression blueprint. We analyzed simultaneously
expression profiles from HCC primary tumors, HCC
PDX models, PDAC primary tumors and PDAC PDX
models. Figure 2A shows the first two dimensions of the
resulting tridimensional expression space (the third axis
is included in Figure S3 in Additional file 1). The four-
group optimal solution of the k-means clustering (CH
index = 228.706) classified human primary PDAC, PDAC
PDX models, human primary HCC and HCC PDX
models separately. It is important to note that the clus-
ters were obtained in an unsupervised manner (that is,
sample labels were not used). Thus, we could check how
many samples were well classified in their original tissue
according to an automatic group selection protocol based
on the expression space. We found that the groups were
reliably classified; in pancreas 100% of PDAC and PDX
models were grouped into their respective groups, while
in liver 88% of primary HCC and 95% of HCC PDXs were
correctly classified. In total, 94% of 256 total samples were
correctly classified.
The first component (Figure 2A, X-axis) explained
30% of the variance and clearly separated the samples by
their tissue of origin, that is, human primary tumors andPDXs from pancreas and human primary tumors and
PDXs from liver clustered separately (Figure 2B). The
second component (Figure 2A, Y-axis) separated PDX
models and primary samples and explained 27% of the
variance. The third axis explains just 8% of the variance
and its incorporation in the expression space supports
that there are four distinct groups of samples. Our clus-
tering results using MCA-based expression spaces were
in agreement with additional analyses using PCA (Figure
S4A in Additional file 1) and hierarchical clustering (Figure
S5 in Additional file 1). It is important to keep in mind
that each axis of a gene expression space represents an
independent source of variance, corresponding to different
underlying gene expression patterns. Moreover, the
sample distributions in the X-axis and Y-axis show
highly significant differences (Wilcoxon’s test P-value =
4.1 × 10−29). Additionally, different clustering of the
samples is obtained when using distances based on
either the X-coordinates (samples grouped according to
the tumor of origin; Figure S5C in Additional file 1) or
the Y-coordinates (samples group according to their
environment; Figure S5D in Additional file 1).
These two significant components imply the co-existence
of two complementary gene expression patterns. The
Figure 2 PDAC and HCC PDX models show transcriptional differences that are not observed in tumor-derived cell lines. (A) First two
dimensions of the gene expression space of PDAC and HCC PDX models and primary tumors (see all three dimensions in Figure S3 in Additional
file 1). This panel represents the result of an optimized iterative k-means clustering, where the optimal number of groups is k = 4. Each line joins a
sample with the centroid of its cluster. (B) Gene expression space of PDAC and HCC cell lines and primary tumors. Optimal k-means clustering for
k = 3. Each line joins a sample with the centroid of its cluster. The points are colored by type of sample class. See PCA results in Figure S4 and
alternative clustering strategies in Figures S5 and S6 in Additional file 1.
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of the tumor of origin (similar expression calls for cells
from the same origin, different calls for those from differ-
ent origins). In contrast, the second component highlights
the effect of an environment-associated expression signal
(similar expression in similar environment, different
expression otherwise). As PDXs in this second axis are
grouped separately from primary tumors, this axis might
represent the loss of part of the gene expression memory
associated with the change of host species.
We performed a similar analysis using cell lines
instead of PDX models. Figure 2B shows the resulting
bi-dimensional gene expression space obtained using ex-
pression profiles from primary PDACs, PDAC cell lines,
primary HCCs and HCC cell lines and which explain
65% of the variance (43% by the first axis and 22% by
the second, Wilcoxon test P-value = 3.99 × 10−13). Re-
markably, while PDX models derived from PDACs and
HCCs form two distinct clusters (Figure 2A), the corre-
sponding cell lines were indistinguishable (Figure 2B;
Figure S6 in Additional file 1). A similar observation,
regarding the higher similarity of cell lines from different
origins, has been previously reported [43]. Our data sug-
gest that, at least for PDAC and HCC, the gene expres-
sion profiles of PDXs remain partially related to the
original tumors, while cell lines’ profiles are not. Ourresults are consistent with previous observations in
breast [2], kidney [3], small cell lung cancer [44] and
uveal melanomas [45] where PDXs maintain key features
of the original tumors, including functional activity and
gene expression profiles. In addition, Daniel et al. [44]
found that genetic divergence between original tumors
and cell lines was higher than genetic divergence
between human primary tumors and PDX models.
Contribution of non-tumoral stromal and immune
infiltrating cells
Substitution of the original stroma of primary tumors
by the murine stroma in PDXs is an important factor
that could partially account for observed differences
between primary tumors and PDXs. In fact, it is widely
acknowledged that tumor samples are virtually always
'contaminated' by non-tumoral stromal and immune
cells. Interestingly, PDX expression data established
using human microarrays should be mostly free from
the contribution of these non-tumoral components.
The combination of the platform species-specificity and
the well-known reduction of non-tumoral components
in PDXs are expected to strongly hinder the detection of
this ever-present 'contamination' in primary tumors. Con-
sequently, the absence of this human 'non-tumoral' con-
tamination in PDXs with respect to primary tumors could
Martinez-Garcia et al. Genome Medicine 2014, 6:27 Page 7 of 13
http://genomemedicine.com/content/6/4/27lead to an overestimation of the differences between them
and primary tumors, as well as of the similarities.
To address this point, we used the ESTIMATE method
[38] to infer the fraction of stromal and immune cells in
the different samples. ESTIMATE is based on a gene sig-
nature characteristic of human tumor-infiltrating stro-
mal and immune cells. According to this method, PDAC
primary tumors show a higher proportion of hNTI cells
than HCC primary tumors (Figure 3A). Both types of
PDXs have very low (negative) ESTIMATE scores, which
indicate that human non-tumoral cells are basically ab-
sent in PDXs, supporting our own experimental observa-
tions. Next, we generated a new gene expression space
using the same samples as in Figure 2A but only using
the 282 genes of this hNTI cell signature. Remarkably, a
totally different gene expression space was obtained,
where the first component is the only informative axis,
explaining as much as 86% of the variance (Figure S7A
in Additional file 1). Interestingly, this first MCA com-
ponent separates the samples in a similar way to the ES-
TIMATE scores (R2 = 0.94, P-value <2.2 × 10−16; Figure
S7B in Additional file 1).
To evaluate the effect of hNTI cells on our results, we
repeated the gene expression space analysis of PDAC
and HCC PDXs and primary tumors (as in Figure 2A)
but excluding the probes mapping to the genes of this
non-tumoral gene signature. Interestingly, removal of
these 282 genes has a minor effect on the sample distri-
bution in the resultant gene expression space (Figure 3B),
showing that these genes were not the main contributors
of the gene expression space. However, when we com-
pared the Y-axis of the expression space generated with-
out the hNTI cell signature genes (Figure 3B) with the
ESTIMATE scores, we observed a striking and veryA) B)
Figure 3 Gene expression from tumor-infiltrating stromal and immun
each of the four groups of samples, where a higher score indicates a highe
samples as in Figure 2A, but excluding genes from the hNTI cell signature.
S7B in Additional file 1. (C) Gene expression space defined after in silico co
to the residuals of the linear regression fits of each MCA component in (B)
the same samples as in Figure 2A, but using only genes from the hNTI cell
analyses using cell lines are shown in Figures S8 and S9 in Additional file 1significant correlation (R2 = 0.83, P-value <2.2 × 10−16;
Figure S7D in Additional file 1; for correlation with
other axes and an equivalent analysis for cell lines see
Figures S7 to S9 in Additional file 1). These results indi-
cate that differences in the contribution of hNTI cells
are a main factor associated with the separated clustering
of primary tumors and PDX models (Y-axis in Figure 2A
and Figure 3B). These findings imply that similarities be-
tween PDX and primary tumors are strongly underesti-
mated by gene expression experiments.
In view of this strong effect, we tried to remove (in
silico) the contribution of non-tumoral cells to the global
gene expression profiles. For this we used simple linear
models for each component with ESTIMATE scores as a
proxy of this contribution (see Materials and methods).
After model-based removal of this trend associated with
the hNTI cell signature, we generated a new gene ex-
pression space corrected for their effect (Figure 3C). In
contrast to the original expression space, the corrected
second component does not separate PDX models from
primary tumors. This suggests that this separation was
attributable to the differential contribution of hNTI cells
to primary tumors and PDXs. In fact, in this corrected
space, PDX models and primary PDAC samples are vir-
tually indistinguishable, while PDXs and primary HCCs
overlap and form a unique cluster.
Ideally, microdissection of the different cell types
would be the best way to determine how each cell type
contributes to the overall gene expression of the tissue.
However, the microdissection of cells in fixed tissues is
associated with higher levels of RNA degradation and
the amplification of partially degraded RNA provokes
potential systemic biases of gene expression [46,47]. In
any case, our data also suggest that the non-tumoralC)
e cells contributes to the expression space. (A) ESTIMATE scores for
r proportion of hNTI cells. (B) Gene expression space using the same
See correlation plot between ESTIMATE score and Y-axis from Figure
rrection of the hNTI cell effect. The coordinates in each axis correspond
(see Materials and methods for details). Complementary analyses with
signature, are shown in Figure S7 in Additional file 1. Complementary
.
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bution to the expression profiles using the Affymetrix
U133 Plus 2.0 human array platform. Other studies have
tried to measure the species-specificity of human microar-
rays in mixtures of human and mouse cells and the
general conclusion was that most of the signal detected is
human-specific [46,48,49]. Current approaches perform-
ing simultaneous quantification by RNAseq of mouse-
specific sequence reads (stromal cells) and human-specific
reads (tumoral cells) will help to better understand the
contribution of the murine stroma to these changes in
gene expression [48,50,51].
Pathway analysis of PDAC PDX models
Because the gene expression of PDAC PDX models
differs from that of the original PDAC tumors, it is
critical to understand the similarities and differences
between these two groups and, in particular, the extent
to which these changes in expression can influence
their validity as preclinical models of drug sensitivity
[1,8,52]. Using the gene expression data, we calculated
the expression frequency (number of times that each
gene can be considered to be 'expressed'; see Materials
and methods) of each gene in both the PDAC primary
tumors and PDX models. Then, we tested if any of the
biochemical and signaling pathways from the Reactome
database [40] were statistically enriched in differentially
expressed genes (see Pathway enrichment analyses section
in Materials and methods).
Figure 4 shows 72 pathways that presented signifi-
cant accumulations of up-regulated or down-regulated
genes (FDR <0.05) in PDXs. These pathways and genes
represent a small number of related cellular functions,
so we grouped them in functional groups. It is particu-
larly interesting that genes in pathways related to cell
cycle and DNA replication are up-regulated in PDX
models while genes in pathways related to signaling trans-
duction, hemostasis and extracellular matrix organization
were significantly down-regulated (Figure 4; Additional
file 2). The genes involved in cell cycle and DNA repli-
cation functional groups are mainly related to chromo-
some segregation and regulation of cell division subgroups.
The overexpression of these genes is in agreement with
the higher proliferation rates of primary tumors engrafted
in mice.
Signal transduction, hemostasis and extracellular matrix
organization functional groups encompass down-regulated
genes in the PDX models; some genes are even com-
mon members in signal transduction and hemostasis
functional groups. Interestingly, many of these func-
tions were previously found altered in the same direc-
tion in breast PDXs [53]. Therefore, the differential
expression of these genes could reflect tumor adapta-
tion to the murine environment. However these down-regulated pathways could also reflect, to some extent,
the substitution of human stroma by murine stroma.
Indeed, we found that stromal genes [38] are signifi-
cantly enriched in hemostasis (P-value = 3.1 × 10−5), sig-
nal transduction (P-value = 1.6 × 10−7) and extracellular
matrix organization (P-value <10−16). Immune genes
[38] are enriched in hemostasis (P-value = 0.02) and
signal transduction (P-value = 6.5 × 10−3). Our results
show that the functional changes detected are affected
by the different contribution of hNTI cells (see above).
Therefore, these and previous functional analyses of
PDXs based on expression arrays should be interpreted
with caution.
Many of the altered biological pathways in PDXs are
typically deregulated in metastatic tumors compared
with primary tumors. In fact, it has been proposed that
PDX models mimic aggressive and/or metastatic tumors
derived from the original primary tumors [42,46,54]. The
tumor engraftment could be seen as a 'forced' meta-
static situation, because the tumor needs to colonize
a new environment to survive. This 'metastasis-like'
phenotype of PDXs is coherent with our results, where
proliferation is activated and signaling and extracellular
matrix proteins change their expression profiles. To
analyze this in more detail, we tested if the functional
groups altered in PDX models were similarly altered in
metastases (compared with primary tumors). We col-
lected two datasets from public databases that contain
data on primary pancreatic tumors and pancreatic me-
tastases located in different organs [32,33]. Considering
the metastases in groups according the colonization
tissue, we performed GSEA analyses comparing each
metastatic group with the corresponding primary tumors.
These results are shown in Additional file 3. Although
some differences were observed between colonization
niches and datasets, pathways altered in PDX models
were, in general, also significantly altered in metastases
in the same direction. As metastatic cell clones repre-
sented only part of the primary tumor population [55],
the cells that succeed engraftment in mice may actually
represent one of the subpopulations of the primary
tumor with higher metastatic potential. Future studies
will be needed to better understand the mechanisms in-
volved in the colonization of new niches by tumor cells,
both in natural metastases in patients and in artificial
PDXs. It will be particularly useful to understand if dif-
ferent locations of colonization may cause differences
in gene expression.
Gene expression stability through passages
We analyzed gene expression profiles obtained from PDX
models at different passages (Additional file 4), where pas-
sage refers to each time a tumor has been re-implanted.
As each passage could accumulate more expression
Figure 4 Functional groups and pathways associated with PDX models and tumor progression. Genes (columns) involved in 46
up-regulated pathways (rows; red), and genes (columns) involved in 26 down-regulated pathways (rows; blue). Pathways are shown on the right,
with colored highlighting representing functional groups. There are two up-regulated and three down-regulated functional groups. For both
up-regulated and down-regulated pathways, only the most significantly differentially expressed genes are shown. Additional file 2 lists core genes
from each pathway with the expression frequency value in the PDX models and human primary tumors.
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http://genomemedicine.com/content/6/4/27changes, we tested if the functional changes previously
described were more pronounced after a higher number
of passages. To this aim, we used a previously published
dataset [42] with samples of primary tumor (F0), 5-
passage PDXs (F5) and 10-passage PDXs (F10) from four
patients. Using these data, we analyzed if the enriched
functional groups described in the previous section (cell
cycle, DNA replication, signaling transduction, hemostasis
and extracellular matrix organization) showed significantdifferences between passages F5 and F10. Figure 5A
shows the expression levels of core genes involved in
the functional groups of altered pathways. Using
GSEA, we confirmed that all functional groups were
altered significantly after engraftment in PDX models
(F0 versus F5 and F0 versus F10). However, none of
the functional groups showed significant changes be-
tween F5 and F10 PDX passages (Figure 5B; Figure
S10 in Additional file 1).
A)
B)
Figure 5 Pathways are altered after tumor engraftment and then stable over passages. (A) Each heatmap represents the standardized
expression levels of the core genes (according to GSEA) from the functional groups significantly altered in PDX models. For each tumor we have
three sampling times: F0 (passage 0, original primary tumor), F5 (fifth passage) and F10 (tenth passage). Color code: red, high; grey, medium;
blue, low. (B) Barplot showing the GSEA normalized enrichment score (NES) for each functional group obtained in the three group comparisons:
F0 versus F5 (left), F5 versus F10 (middle) and F0 versus F10 (right). The color code used is the same as in Figure 3. Significantly enriched
functional groups (FDR <0.005) are indicated with three asterisks.
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http://genomemedicine.com/content/6/4/27Taken together, these data suggest that these func-
tional changes occur in the initial adaptation to the new
environment after engraftment but no major changes
occur afterwards. In other words, the gene expression
pattern is stable, in agreement with previous studies in
systems such as small-cell lung cancer [44], uveal mela-
nomas [45] or colorectal cancer [52].
Conclusions
The mouse niche environment affects tissue xenografted
in mice, with some alterations in the transcriptome. The
lack of immune and stromal infiltrating cells in PDXs
seems to be an important contributor to these changes.
Thus, caution is needed when research results using
PDX models are translated to patients. Still, the tran-
scriptomes of PDX models of PDACs and HCCs retain
important aspects of their tissue of origin.
Our work has three important implications. First,
PDAC (and HCC) PDX models retain gene expression
similarities with the primary tumors, while cell lines do
not. These results are in agreement with the better
results in drug sensitivity prediction generally obtained
with PDX models [11,44]. Second, some functional pro-
cesses are altered in tumor cells after engraftment. Our
results also show that metastases and PDX models share
some functional alterations regarding primary tumors.
Given that metastases frequently occur in pancreas can-
cer patients, our future work will focus on understand-
ing the similarities and differences between primary and
metastatic PDX models. Third, although these pathways
show distinct profiles in PDX models compared with
original primary tumors, they appear to be stable over
passages. In our view, the stability in gene expression in
PDAC PDX models over different passages is of major
relevance and favors the validity of this preclinical model
of disease.
Additional files
Additional file 1: Supplementary figures.
Additional file 2: Table S1. Core genes from each pathway with the
expression frequency value in the PDX models and human primary
tumors and presence or absence in each functional group.
Additional file 3: Table S2. GSEA results for pathways altered in PDX
models in metastases. Table contains FDR values of functional groups for
each comparison between primary tumor and different metastases
obtained from two datasets [32,33].
Additional file 4: Table S3. Information about origin of PDXs and
microarray hybridization, the publication status of expression data and
number of passages of PDX models.
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